Following a win for Bavencio, Pfizer and Merck KGaA continue PD-L1 losing streak
Almost two years ago Pfizer and Merck KGaA conceded that their PD-L1 drug failed to significantly improve overall survival for gastric cancer patients in the third-line setting. We now know that Bavencio doesn’t work as a first-line maintenance therapy, either.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.